Verofarm OAO : OJSC “VEROPHARM” announces operational performance indicators for the first 9 months of 2013

PRESS-RELEASE

FOR IMMEDIATE DISTRIBUTION

JANUARY 23, 2014 OJSC "VEROPHARM" announces operational performance indicators for the first 9 months of 2013 Rx drugs

According to the results for the first 9 months of 2013 total sales of the top five best selling Rx drugs amounted to RUR 1,145.2 million, which corresponds to 43.8% of sales in the Rx drugs segment and 31.8%[1] of the Company's total sales.
According to the results of the first 9 months of 2013 the top five best selling Rx drugs are:
o Geptor (Ademetionine; ATC[2] «Digestive tract and metabolism»); sales increased by
31.2% as compared to the same period of the previous year; 14.4% of sales in the Rx
drugs segment;

o Tautax (Docetaxel; A TC «A ntineoplastic and immunomodulating agents»); sales in the segment made 10.1%;

o Cerepro (Choline Alfoscerate; ATC «Medications for the treatment of the nervous system deseases»); sales in the segment made 8.6%;

o Irunine (Itraconazole; ATC «Antimicrobials for systematic use»); sales in the segment made 6.0%;

o Parclitaxel-LENS (Parclitaxel; A TC «A ntineoplastic and immunomodulating agents»);

sales in the segment made 4.7%;

OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 98.4% of sales.

o Xilen (Xylometazoline; ATC «Medications for the treatment of respiratory system»);

sales in the OTC drugs segment made 45.0%;

o Slabilen (Sodium picosulfate; ATC «Alimentary tract and metabolism»); sales in the

OTC drugs segment made 33.2%;

o Motilak (Domperidone; ATC «Alimentary tract and metabolism»); sales in the OTC

drugs segment made 16.2%;

o Vitasharm and Vitatress (AT C «Vitamins»); sales in the OT C drugs segment made 3.2%;

o Ginkgo biloba (Ginkgo biloba; A TC «Medications for the treatment of urogenital organs»); sales in the OTC drugs segment made 0.8%.

107023, Mos cow, Rus s ia, Ochakovskoe shosse, 10-2-1, tel.: [phone]

Traditional drugs segment

According to the results of 9 months of 2013 the top five best selling prescription medications are:

o Vero-Dexamethasone (Dexamethasone; ATC «Hormonal drugs for systematic use»);

sales in the traditional drugs segment made 42.1%;

o Pyridoxine (ATC «Alimentary tract and metabolism»); sales in the segment made

22.1%;

o Vero-Ciprofloxacin (Ciprofloxacin; ATC «Antimicrobials for systematic use»); sales in the segment made 12.9%;

o Vero-Loperamide (Loperamide; ATC «Alimentary tract and metabolism»); sales in the segment made 12.7%;

o Vero-Flukonazole (Fluconazole; ATC «Antimicrobials for systematic use»); sales in the segment made 5.4%;

Non-pharamaceutical products

According to the results of 9 months of 2013 the top five best selling non-pharamaceutical products are:

o Conventional antimicrobial adhesive bandages; 35.7% of sales in the segment;

o Conventional reel adhesive bandages; 24.5% of sales in the segment; o Therapeutic patches - pepper plasters; 18.2% of sales in the segment; o Therapeutic patches - corn plasters; 14.4% of sales in the segment;

o Condoms; 4.0% of sales in the segment.

NEW DRUGS PRODUCT ION AND SALES

During 9 months of 2013 Veropharm launched production and sales of the following new drugs:

o A nfibra (Enoxaparin sodium; A TC «Medications affecting hematogenesis and blood»);

o Salbutamol (Salbutamol; ATC «Medications for the treatment of respiratory system»);

o ACP (Escitolapram, ATC «Medications for the treatment of the nervous system deseases»);

o Gistamel (Imatinib; A TC « A ntineoplastic and immunomodulating agents»);

o Bereta (Rabeprazole; A TC «Alimentary tract and metabolism»)

For 9 months of 2013 Veropharm has initiated the sales of condoms under its own brand name:

o «Sensex» (Condoms; A TC «Medical items»).

NEW DRUGS REGIST RAT ION

During 9 months of 2013 Veropharm received registration for the following 2 drugs:

107023, Mos cow, Rus s ia, Ochakovskoe shosse, 10-2-1, tel.: [phone]

o ACP (Escitolapram, ATC «Medications for the treatment of the nervous system deseases»);

o Gistamel (Imatinib; A TC « A ntineoplastic and immunomodulating agents»)

And the the following non-medical products:

o Detoksiver - dietary supplement;

o 8 dietary products for weight control "Nutrico Diet®";

o 9 perfume and cosmetic products.

At present 41 products are in the development plan and 23 drugs are currently at different stages of the registration process.

[1] % - percent of finished goods sales

[2] ATC - anatomico-therapeutico-chemical group

For further information please call Veropharm OJSC:

M aksutova Nadiya,

Chief Financial Officer

mak sutova.nadiya@verop ha rm.rutel. ([phone]

Or visit web-site of the Company www.veroph arm. ru

Notes to the Editor:

VEROPHARM OJSC is one of the largest Russian pharmaceutical manufacturers.

Shares of the Company are traded at MICEX (ticker: VFRM). Market capitalization of the Company as of

December 23, 2013 totaled RUR 9,350 billion (according to RTS).

The charter capital of the Company makes 10 million ordinary shares.

VEROPHARM OJSC is the market leader in Russia for production of plasters and oncological medicines. The Company's production facilities comprise 3 pharmaceutical plants in Belgorod, Voronezh and Pokrov. The Company's product portfolio includes more than 300 items. VEROPHARM OJSC employs more than 1,700 people.

In the annual research conducted by the portal SuperJob.ru among Russian companies OJSC "VEROPHARM" is recognized as one of the most attractive employers in the labor market and is awarded the status of "Attractive employer-2012".

According to IMS Health, following the results of 9 months of 2013 Veropharm occupies the 6th position in the

rating "Russian pharmaceutical manufacturers in production volume terms".

According to IMS Health, following the results of 9 months of 2013, as compared to the same period of the previous year, Veropharm takes the following positions among Russian and foreign manufacturers in the rating "Oncology drugs manufacturers":

o 8th place in monetary terms

o 1st place in physical terms (occupies the leading position).

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION.

107023, Mos cow, Rus s ia, Ochakovskoe shosse, 10-2-1, tel.: [phone]

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This docum ent m ay include s tatem ents that are "forward -looking s tatem ents ", including future operating res ults of the Com pany. Thes e forward-looking s tatements involve ris k and uncertainty regarding im plem entation of future activities . As a res ult, actual future res ults m ay differ m aterially from the plans , goals and expectations s et out in thes e forward -looking s tatem ents . The Com pany undertakes no obligation to change thes e s tatem ents to reflect actual res ults .

This docum ent does not contain a public offer to purchas e s ecurities in the US. The s ecurities referred to herein have not been and will not be regis tered under the US Secu rities Act of 1933, as am ended (the "Securities Act"), and m ay not be offered or s old in the United States or to US pers ons .

This com m unication is being distributed only to and is directed only at (a) pers ons outs ide the United Kingdom , (b) pers ons who have profes s ional experience in m atters relating to inves tm ents , i.e., inves tm ent profes s ionals within the m eaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Prom otion) Order 2005 (the "Order"), and (c) high net worth com panies , unincorporated as s ociations and other bodies to whom it m ay otherwis e lawfully be com m unicated in accordance with Article 49 of the Order (all s uch pers ons together being referred to as "relevant pers ons "). The s ecurities are available only to, and any invitation, offer or agreem ent to s ubs cribe, purchas e or otherwis e acquire s uch s ecurities will be available only to or will be engaged in only with, relevant pers ons . Any pers on who is not a relevant pers on s hould not ac t or rely on this com m unication or any of its contents .

107023, Mos cow, Rus s ia, Ochakovskoe shosse, 10-2-1, tel.: [phone]